Rituxan Sales Data

Rank 12 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Rituxan U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 12 (1) 1.25% 1.30%
Q3 2013 11 -4.46% -5.78%
Q2 2013 11 3.96% 1.96%
Q1 2013 11 1.98% 1.82%
Q4 2012 11 0.72% -1.26%
Q3 2012 11 (1) -5.61% -3.30%
Q2 2012 12 (3) 8.26% 5.30%
Q1 2012 15 (1) -1.91% -0.91%
Q4 2011 14 (2) 6.96% 4.74%
Q3 2011 16 -1.77% -1.86%
Q2 2011 16 (4) 7.26% 5.09%
Q1 2011 20

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
February 19, 2010Rituxan Approved for Chronic Lymphocytic Leukemia
February 19, 2010Roche's Rituxan Gets US OK For Another Cancer
November 25, 2009Type 1 Diabetes May Have a New Foe
November 19, 2009Genentech, Biogen Get FDA Request on Rituxan
October 23, 2009Rituxan (rituximab) - Third case of PML reported, the first case of PML in a patient with rheumatoid arthritis treated with Rituxan who has not previously received treatment with a TNF antagonist
March 13, 2009Cancer Drug May Offer New Hope for Lupus Patients
Hide
(web4)